Implementing Depression and Adherence Treatment
NCT07032363
AIDS, Acquired Immunodeficiency Syndrome
Miami, Florida, United States
View Trial DetailsNCT Number: NCT01206920
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.
Interested in participating?
Request InfoAll sexes
Observational
Children's National Medical Center--Pediatric Clinic, Washington D.C., District of Columbia, United States
All major community and academic clinics treating persons with HIV in the District of Columbia (DC) are included in the "DC Cohort", with consideration to be given subsequently to the inclusion of large private physician practices. Recruitment of persons at higher risk for acquiring HIV will occur in selected clinics based on the numbers of persons estimated to be receiving HIV preventive services at those clinics. Socio-demographics, risk factors, treatments, diagnoses, labs and procedures documented in outpatient medical record systems will be included in the DC Cohort database. Routine reports will be generated every quarter for sites comparing their participants' socio-demographics, clinical status, treatments, and outcomes to all other data in the DC Cohort database, and other comparisons specifically requested by sites. All sites will be provided analytic support in research areas of interest.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Treatment Cohort Inclusion Criteria:
Treatment Cohort Exclusion Criteria:
Prevention Cohort Inclusion Criteria:
Persons receiving any antiretroviral prescription without evidence of HIV or Hepatitis B infection
Patients with a Z29.81 Encounter for HIV pre-exposure prophylaxis
Time frame: through study completion, an average of 10 years from enrollment to the end of study follow up
The study will assess rates of viral suppression (defined as an HIV RNA test less than 200 copies/ml) from enrollment to 10 years post enrollment.
Time frame: through study completion, an average of 5 years from enrollment to the end of study follow up period
Persons who are receiving HIV preventive services will be followed longitudinally to assess time to HIV positivity from baseline to 5 years post enrollment
Contact information is provided by the study sponsor or research team.
Amanda D Castel, MD, MPH
CONTACT
Megan O'Brien, PhD, MPH
CONTACT
George Washington University
Other
Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort
Acronym: DC Cohort
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07032363
AIDS, Acquired Immunodeficiency Syndrome
Miami, Florida, United States
View Trial DetailsNCT06585631
AIDS, Acquired Immunodeficiency Syndrome
Baltimore, Maryland, United States
View Trial DetailsNCT06202898
AIDS, Acquired Immunodeficiency Syndrome
Orlando, Florida, United States
View Trial DetailsNCT03670316
AIDS, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial Details